Trial Profile

A Pilot Electroencephalography (EEG) Study to Evaluate the Effect of CT1812 Treatment on Synaptic Activity in Subjects With Mild to Moderate Alzheimer's Disease

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 01 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Zervimesine (Primary)
Indications Alzheimer's disease
Focus Adverse reactions; Biomarker; Pharmacokinetics; Therapeutic Use
Acronyms SEQUEL
Sponsors Cognition Therapeutics

Most Recent Events

22 Aug 2024 According to a Cognition Therapeutics media release, data from this trial were published in The Journal of Prevention of Alzheimers Disease.
22 Aug 2024 Results published in the Media Release
06 Mar 2024 According to a Cognition Therapeutics media release, presenting results of proteomic analyses in posters at the AD/PD 2024 Alzheimer's & Parkinson's Diseases Conference (March 5-9, 2024 in Lisbon, Portugal).

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com